Selisistat ( DrugBank: Selisistat )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
8ハンチントン病3

8. ハンチントン病


臨床試験数 : 242 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-001131-23-GB
(EUCTR)
24/10/201118/07/2011A study to determine how safe and tolerable the study drug is, when given to patients with Huntingtons Disease.A double-blind, placebo-controlled study in Huntington’s Disease patients to determine the safety and tolerability of SEN0014196 - N/A Huntington's disease
MedDRA version: 14.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: SEN0014196
Product Code: SEN0014196
INN or Proposed INN: selisistat
Product Name: SEN0014196
Product Code: SEN0014196
INN or Proposed INN: selisistat
Siena Biotech SpANULLNot RecruitingFemale: yes
Male: yes
144Germany;Italy;United Kingdom
2EUCTR2011-001131-23-IT
(EUCTR)
20/10/201122/11/2011A study to determine how safe and tolerable the study drug is, when given to patients with Huntingtons Disease.A double-blind, placebo-controlled study in Huntington's Disease patients to determine the safety and tolerability of SEN0014196 Huntington's disease
MedDRA version: 14.0;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 14.0;Level: LLT;Classification code 10020469;Term: Huntington's chorea;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: SEN0014196
Product Code: SEN0014196
INN or Proposed INN: selisistat
Product Name: SEN0014196
Product Code: SEN0014196
INN or Proposed INN: selisistat
SIENA BIOTECH SPANULLNot RecruitingFemale: yes
Male: yes
144Germany;United Kingdom;Italy
3EUCTR2011-001131-23-DE
(EUCTR)
21/09/201127/06/2011A study to determine how safe and tolerable the study drug is, when given to patients with Huntingtons Disease.A double-blind, placebo-controlled study in Huntington’s Disease patients to determine the safety and tolerability of SEN0014196 - N/A Huntington's disease
MedDRA version: 14.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: SEN0014196
Product Code: SEN0014196
INN or Proposed INN: selisistat
Product Name: SEN0014196
Product Code: SEN0014196
INN or Proposed INN: selisistat
Siena Biotech SpANULLNot RecruitingFemale: yes
Male: yes
144Germany;Italy;United Kingdom